Page last updated: 2024-10-15

2'-guanylic acid

Description

2'-guanylic acid: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

guanosine 2'-monophosphate : A purine ribonucleoside 2'-monophosphate having guanine as the nucleobase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135460966
CHEBI ID74948
SCHEMBL ID1477429
MeSH IDM0087414

Synonyms (38)

Synonym
2GP ,
guanosine-2'-monophosphate
DB01937
1RNT
1RGL
2'-gmp
2'-o-phosphoguanosine
guanosine 2'-phosphate
2'-guanylic acid
[(2r,3r,4r,5r)-2-(2-amino-6-oxo-3h-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate
guanosine 2'-monophosphate
SCHEMBL1477429
c.i. reactive red 16
12238-07-2
2'-guanosine monophosphate
130-50-7
12237-00-2
c.i. reactive red 31
CHEBI:74948
WTIFIAZWCCBCGE-UUOKFMHZSA-N
reactive red 15
[(2r,3r,4r,5r)-2-(2-amino-6-oxo-1h-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate
12238-01-6
12237-24-0
12237-02-4
12222-03-6
12223-03-9
12237-07-9
Q27145031
(2r,3r,4r,5r)-2-(2-amino-6-oxo-3,6-dihydro-9h-purin-9-yl)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-3-yl dihydrogen phosphate
12222-09-2
solvent blue 70
reactive red 49
c.i. reactive red 55
direct blue 244
c.i.disperse blue 108
c.i.direct blue 165
reactive red 31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.1.27.3 (ribonuclease T1) inhibitorAn EC 3.1.27.* (endoribonucleases producing other than 5'-phosphomonoesters) inhibitor that interferes with the action of ribonuclease T1 (EC 3.1.27.3).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
purine ribonucleoside 2'-monophosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, RIBONUCLEASE T1Aspergillus oryzaeKd37.000037.000037.000037.0000AID977611
Chain A, RIBONUCLEASE T1Aspergillus oryzaeKd37.000037.000037.000037.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1992Journal of molecular biology, May-20, Volume: 225, Issue:2
RNase T1 mutant Glu46Gln binds the inhibitors 2'GMP and 2'AMP at the 3' subsite.
AID1811Experimentally measured binding affinity data derived from PDB1992Journal of molecular biology, May-20, Volume: 225, Issue:2
RNase T1 mutant Glu46Gln binds the inhibitors 2'GMP and 2'AMP at the 3' subsite.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (20.00)18.7374
1990's17 (68.00)18.2507
2000's0 (0.00)29.6817
2010's3 (12.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]